Table 1 Initial patient characteristics.
Gender (male/female; n) | 60/88 |
|---|---|
Age at inclusion (median (IQR); years) | 35 (28–45) |
Disease duration (median (IQR); years) | 15 (10–20) |
Smoking (No, Yes, Stopped; %) | 75.2/17.8 / 7 |
Age at CD diagnosis (Montreal A1 / A2 / A3; %) | 17.5/70.8 / 11.7 |
Location (Montreal L1 / L2 / L3 / + L4; %) | 16.9/22 / 55.9 / 5.2 |
Behavior (Montreal B1 / B2 / B3; %) | 51.1/26.3 / 22.6 |
Perianal manifestation (%) | 45.6 |
Previous resective surgery (%) | 46.3 |
Previous perianal surgery (%) | 46.2 |
Previous immunosuppressive therapy (%) | 82.4 |
Previous anti-TNF therapy (None / IFX / ADA / IFX + ADA; %) | 2.8/14.2/19.9/63.1 |
Previous vedolizumab therapy (%) | 25.9 |
Follow-up time (median (IQR); weeks) | 166 (144–186) |
